Quarterly report pursuant to Section 13 or 15(d)

Note 3 - License Supplier Agreement (Details Textual)

v3.23.3
Note 3 - License Supplier Agreement (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 4 Months Ended 9 Months Ended
Apr. 28, 2023
Mar. 30, 2023
Feb. 28, 2023
Oct. 29, 2018
Dec. 31, 2019
Sep. 30, 2023
Jun. 17, 2015
Sep. 30, 2023
Contractual Obligation Development Expense         $ 81,500      
Contractual Obligation, Commercial Expense         $ 151,000      
Stock Issued During Period, Value, License Expense           $ 0   $ 1,230
AnnJi [Member]                
License Agreement, Purchase Consideration     $ 3,000          
Payments to Acquire License $ 2,000              
Acquired License Payable Within 180 Days     1,000          
Maximum Reimbursement Amount In Connection With Product Clinical Trial     10,800          
Maximum Reimbursement Amount In Connection With Certain Development Milestones     14,500          
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone     27,500          
Maximum Reimbursement Amount Upon Achievement of Sales Milestone     $ 165,000          
Stock Issued During Period, Shares, License Expense (in shares)   831,618            
Stock Issued During Period, Value, License Expense   $ 900            
Stock Issuable During Period, Shares, Upon Enrollment of Patient (in shares)     276,652          
Stock Issuable During Period, Value, Upon Enrollment of Patient     $ 300          
AnnJi [Member] | Minimum [Member]                
Sales Milestone Required for Maximum Reimbursement     75,000          
Annual Sale Threshold for Royalty Payment     50,000          
AnnJi [Member] | Maximum [Member]                
Sales Milestone Required for Maximum Reimbursement     750,000          
Annual Sale Threshold for Royalty Payment     $ 300,000          
Revogenex License [Member]                
Contractual Obligation, Maximum Future Payments             $ 3,000  
Baergic Licenses [Member] | CCHMC [Member]                
Percentage of Equity Fee         5.00%      
Polpharma [Member]                
Payments to Acquire in Process Research and Development       $ 2,000        
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Upfront Payment [Member]                
Payments to Acquire in Process Research and Development             2,000  
Percentage of Equity Fee         20.00%      
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Additional Payment [Member]                
Payments to Acquire in Process Research and Development         $ 1,000   $ 1,000  
Baergic Licenses [Member] | Upfront Payment [Member] | CCHMC [Member]                
Payments to Acquire in Process Research and Development         200      
Baergic Licenses [Member] | Upfront Payment [Member] | AZERBAIJAN                
Payments to Acquire in Process Research and Development         $ 3,000      
AnnJi [Member]                
Right to Sell Common Stock, Price Per Share (in dollars per share)     $ 2.1